MedTrace Logo

Topoisomerase II Alpha Gene Amplification and Protein Overexpression Predicting Efficacy of Epirubicin

NCT00162812 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 338

Last updated 2008-07-18

No results posted yet for this study

Summary

prospective evaluation of topoisomerase II alpha gene amplification and protein overexpression as markers predicting the efficacy of epirubicin in the primary treatment of breast cancer patients.

Conditions

Interventions

DRUG

Epirubicin

100 mg/m² every three weeks (4 cycles) or every two weeks (6 cycles)

Sponsors & Collaborators

  • Gustave Roussy, Cancer Campus, Grand Paris

    collaborator OTHER

  • Centre Paul Strauss

    collaborator OTHER

  • Centre Hospitalier du Luxembourg

    collaborator OTHER

  • Clinique Louis Cathy - Baudour - Belgium

    collaborator UNKNOWN

  • HIS - Site Etterbeek - Ixelles - Belgium

    collaborator UNKNOWN

  • Clinique Saint Pierre Ottignies

    collaborator OTHER

  • Clinique Ste Elisabeth - Namur - Belgium

    collaborator UNKNOWN

  • University Hospital of Crete

    collaborator OTHER

  • Feculdade de Medicina da Universidade de Sao Paulo - Brasil

    collaborator OTHER

  • Jules Bordet Institute

    lead OTHER

Principal Investigators

  • Veronique D'Hondt, MD, PhD · Jules Bordet Institute

  • Martine Piccart, MD, PhD · Jules Bordet Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-01-31
Primary Completion
2008-12-31
Completion
2009-04-30

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00162812 on ClinicalTrials.gov